Meeder Asset Management Inc Macrogenics Inc Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$15.91 - $21.88 $1,877 - $2,581	-118 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$19.74 - $28.7 $43,210 - $62,824	-2,189 Reduced 94.89%	118 $2,000
Q2 2021 Aug 09, 2021	BUY	$20.49 - $35.63 $47,270 - $82,198	2,307 New	2,307 $62,000
Q4 2020 Feb 09, 2021	SELL	$19.41 - $26.0 $71,952 - $96,382	-3,707 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$24.69 - $31.6 $938 - $1,200	-38 Reduced 1.01%	3,707 $92,000
Q2 2020 Aug 11, 2020	BUY	$5.2 - $29.12 $13,884 - $77,750	2,670 Added 248.37%	3,745 $104,000
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $3,060 - $8,658	715 Added 198.61%	1,075 $6,000
Q4 2019 Feb 13, 2020	BUY	$7.95 - $12.27 $2,862 - $4,417	360 New	360 $4,000
Q1 2019 Apr 16, 2019	SELL	$11.11 - $25.6 $133,686 - $308,044	-12,033 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$11.75 - $21.42 $138,532 - $252,541	11,790 Added 4851.85%	12,033 $153,000
Q3 2018 Nov 02, 2018	BUY	$19.26 - $23.46 $96 - $117	5 Added 2.1%	243 $0
Q2 2018 Jul 24, 2018	BUY	$19.78 - $24.67 $3,382 - $4,218	171 Added 255.22%	238 $0
Q1 2018 May 03, 2018	BUY	$18.89 - $32.46 $1,265 - $2,174	67 New	67 $2,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.